Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment
Status:
Completed
Trial end date:
2019-10-17
Target enrollment:
Participant gender:
Summary
The study is conducted to confirm equivalence between QL1012 (a new biosimilar formulation of
Recombinant Human Follicle-stimulating Hormone) and Gonal-f® with respect to the number of
oocytes retrieved in women for assisted reproductive treatment.